Remede System Approved for Central Sleep Apnea

Share this content:
Remede System Approved for Central Sleep Apnea
Remede System Approved for Central Sleep Apnea

MONDAY, Oct. 9, 2017 (HealthDay News) -- The Remede sleep system, an implanted device that treats central sleep apnea, has been approved by the U.S. Food and Drug Administration.

The new system, including a battery pack implanted in the chest, stimulates the phrenic nerve and monitors a patient's lung function during sleep, the FDA said.

In clinical testing involving 141 individuals, the apnea hypopnea index was reduced by at least half among 51 percent of people who used the system. That compared with an 11 percent reduction among those who didn't have the system implanted.

The most common adverse reactions included implant-site infection and swelling near the implant site. The system should not be implanted in people with an active infection or among people who require use of a magnetic resonance imaging machine, the FDA said.

The system is produced by Respicardia Inc., based in Minnetonka, Minnesota.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

More U.S. Teens Are Vaping, but Use of Opioids, Alcohol Falling

More U.S. Teens Are Vaping, but Use of ...

About 37 percent of 12th graders said they had vaped within the previous 12 months

Type 2 Diabetes Risk Lower in Women With Active Migraine

Type 2 Diabetes Risk Lower in Women With ...

Prevalence of active migraine decreased linearly in the 24 years prior to diabetes diagnosis

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Treatment costs less than extended-release naltrexone without negative impact on outcomes

is free, fast, and customized just for you!




Already a member?

Sign In Now »